Reputation and trust are important aspects of business today. No company can get out of drawing up guidelines and procedures to be sure that the laws and regulations are properly adhered to. The customary term used for this is compliance. This nicely fits in with Johnson & Johnson’s core values and standards as worded in Our Credo. 

Responsible marketing and communication are an inherent part of this. Our Credo, the code of ethics of pharma.be (General Union of the Pharmaceutical Industry in Belgium), the Mdeon guidelines (Mdeon is the shared ethical platform made up of associations of doctors, pharmacists, veterinary surgeons, dentists, nursing staff, the pharmaceutical industry and the medical resources industry) and relative Belgian law comprise the basis here. 

In practical terms this refers to the responsibility the company has relating to the adequate training and continuous education of its staff, so responsible and ethical communication is ensured at all time and interaction with doctors, patients, the general public and other parties involved takes place in a correct way.

All promotional material is created with great exactitude so it is always in line is with the applicable regulations and laws, while also reflecting current state of scientific advance.

As a company we also take responsibility for the further training of doctors and pharmacists concerning our medicines and the therapeutic domains in which we operate. We only wish to offer further training of the highest quality. Since 2011 we have been doing this in the Benelux under the under the auspices of the Janssen Academy. Janssen Academy has the purpose of offering high quality further medical/scientific training in cooperation with the medical target groups and other relevant parties. In 2012 the Janssen Academy facilitated the participation of 834 physicians in medical/scientific further training shared across 121 educational events (congresses and symposiums).

Doc_man_document_gang.jpg

Durabilité
Économique

Janssen believes that strong corporate results, correct policies and focused activities pave the way towards economic sustainability. 

Janssen must constantly reinvent itself in order to cope with the structural and economic changes that affect its environment. This is why Janssen is committed to build partnerships within an open innovation model, and to the continuous alignment of its cost-competitiveness by only developing medicines with a high therapeutic added value. 

For Janssen this means specifically: being focused and a leader in research & development, and being efficient and progressive in terms of production with the aim of bringing new therapeutic solutions to patients quicker and at less expense, and implementing a growth strategy to ensure our continued investment in all these areas.